Chief Science Officer
Dr. Baxter works at the intersection of innovation and biotechnology, and brings a wealth of expertise in biochemistry, nanotechnology and entrepreneurship.
Dr. Baxter is a former Program Director with the Divison of Industrial Innovation and Partnerships at the National Science Foundation, the world's largest early stage investment vehicle for startup companies. The Program's mission is to transform scientific discovery into societal and economic benefit by catalyzing private sector commercialization of technological innovations. The program increases the incentive and opportunity for startups and small businesses to undertake cutting-edge, high-quality scientific research and development. Dr. Baxter has deployed hundreds of millions of dollars into early stage businesses.
Dr. Baxter is the Founder and former Chief Science Officer of Hurel Corporation, a biotechnology company. He is the Founder and Chief Science Officer of Aegen Biosciences.
Dr. Baxter is a long-time mentor and member of the Founders Board of Advisors at StartX Stanford Student Startup Accelerator and was a Fellow with the Innovation Accelerator, a public private partnership with the National Science Foundation to facilitate the commercialization efforts of small businesses.
Dr. Baxter is an Adjunct Associate Professor with the Department of Biomedical Engineering at Cornell University and was a Senior Scientist at the Cornell Nanoscale Science and Technology Facility and the Biotechnology Liaison for the National Nanofabrication Users Network.
Dr. Baxter is a published author and holds over 20 patents on various aspects of molecular biology and biochemistry. He serves on the Board of Certichem, Inc and is the Chair of the Science Advisory Board of Stellar BioTechnologies.
As a Chief Science Officer, Dr. Baxter leads the innovation outreach and is focused on assessing the health impacts of chemicals and new materials. He mentors accelerator companies on life sciences innovation and entrepreneurship; IP protection, Freedom to operate; Investor relations and best business practices.